Psoriasis Drug Market

Psoriasis Drug Market Analysis and Forecast by Fact.MR

• The global psoriasis drug market is estimated at US$ 23.3 billion in 2025 and has been forecast to expand at a CAGR of 11.0% to reach US$ 73.4 billion by 2036.
• The psoriasis drug market encompasses biologic therapies, topical treatments, and systemic immunosuppressants used to manage plaque psoriasis, psoriatic arthritis, and related inflammatory skin conditions.
• Biologic therapies, including TNF inhibitors, IL-17 inhibitors, and IL-23 inhibitors, account for the largest product share by revenue.
• Injectable administration is the dominant route for biologic products, while topical corticosteroids lead the non-biologic segment.
• Hospital pharmacies serve as the primary distribution channel.

Summary of Psoriasis Drug Market

• Market Snapshot
  • In 2025, the global Psoriasis Drug Market was valued at approximately USD 23.3 billion.
  • The market is estimated to reach USD 25.9 billion in 2026 and is projected to attain USD 73.4 billion by 2036.
  • The psoriasis drug market is likely to expand at a CAGR of 11.0% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 47.6 billion between 2026 and 2036.
  • Biologic Therapies accounts for 42.6% of product share in 2026.
  • India (12.1%) and China (11.6%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • IL-23 inhibitor class expansion with guselkumab, risankizumab, and tildrakizumab is shifting treatment algorithms toward targeted biologic therapy with superior long-term efficacy data.
  • Biologic therapy adoption is expanding from dermatology into rheumatology as psoriatic arthritis indication approvals broaden the eligible patient population.
  • Oral PDE4 inhibitor and TYK2 inhibitor development is creating an oral small molecule alternative to injectable biologics for moderate psoriasis patients.
  • Emerging market biologic access programs and patient assistance are expanding the global biologic-eligible population beyond developed market healthcare systems.
  • Real-world evidence from registries and observational studies is strengthening the clinical case for earlier biologic initiation rather than step-through failure of conventional therapies.
• Product and Segment View
  • Biologic Therapies accounts for 42.6% of the product segment in 2026, supported by strong installed base and continued procurement across primary end use channels.
  • Biologics accounts for 44.1% of the drug class segment in 2026, reflecting concentrated demand across established application areas.
  • Injectable accounts for 46.3% of the route of administration segment in 2026, with adoption rising across both developed and emerging markets.
  • Key segmentation includes:
    • Product: Biologic Therapies, Topical Therapies, Systemic Therapies
    • Drug Class: Biologics, Immunosuppressants, Anti Inflammatory Agents
    • Route of Administration: Injectable, Topical, Oral
    • Disease Severity: Moderate Psoriasis, Psoriatic Arthritis Associated Psoriasis, Mild Psoriasis
  • These systems enable:
    • Targeted procurement and specification alignment across buyer segments
    • Performance benchmarking across product and application categories
    • Regional demand mapping across 30 plus countries
• Geography and Competitive Outlook
  • North America accounts for a large share of global demand, supported by established procurement channels and a mature buyer base.
  • Europe shows stable demand, with Germany (9.8%) contributing through regulatory compliance and institutional procurement for psoriasis drug products.
  • Asia Pacific demand is led by India (12.1%) and China (11.6%).
  • India (12.1%) and China (11.6%) are the fastest growing country markets during the forecast period.
  • Leading companies include AbbVie Inc., Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Novartis AG, Eli Lilly and Company.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The psoriasis drug market is undergoing a generational shift from TNF inhibitor dominance to IL-23 inhibitor leadership, with oral TYK2 inhibitors creating a parallel growth vector. AbbVie leads through its transition from Humira to Skyrizi, while J&J (Tremfya), Novartis (Cosentyx), and Eli Lilly (Taltz) compete across the biologic landscape. Growth will be driven by biologic penetration expansion in emerging markets, IL-23 class consolidation as the preferred first-line biologic, and oral therapy development for patients preferring non-injectable treatment. The market is structurally positive with multiple growth drivers operating simultaneously.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• IL-23 inhibitor class expansion with guselkumab, risankizumab, and tildrakizumab is shifting treatment algorithms toward targeted biologic therapy with superior long-term efficacy data.
• Biologic therapy adoption is expanding from dermatology into rheumatology as psoriatic arthritis indication approvals broaden the eligible patient population.
• Oral PDE4 inhibitor and TYK2 inhibitor development is creating an oral small molecule alternative to injectable biologics for moderate psoriasis patients.

Key Market Constraints

• High biologic therapy cost creates payer access barriers and prior authorization requirements that restrict treatment to patients who fail conventional therapies.
• Biosimilar entry for TNF inhibitors (adalimumab, etanercept, infliximab) is compressing revenue in the oldest biologic class while expanding patient access.
• Patient injection burden and preference for non-injectable treatments create a demand gap that oral small molecule therapies are positioned to fill.

Key Opportunity Areas

• TYK2 inhibitor oral therapies (deucravacitinib) represent a new mechanism class that could capture patients unwilling or unable to use injectable biologics.
• Biologic combination approaches and sequential biologic strategies for refractory psoriasis are creating multi-product treatment protocols.
• Emerging market biologic access in India, China, and Latin America represents a large untapped patient population where disease prevalence is substantial but biologic penetration is minimal.

Segment-wise Analysis of the Psoriasis Drug Market

• Biologic Therapies holds 42.6% of the product segment in 2026, supported by established demand channels and continued procurement across primary end use applications.
• Biologics holds 44.1% of the drug class segment in 2026, supported by established demand channels and continued procurement across primary end use applications.
• Injectable holds 46.3% of the route of administration segment in 2026, supported by established demand channels and continued procurement across primary end use applications.

The psoriasis drug market is segmented by product, drug class, route of administration, disease severity, and region.

By product, the market covers Biologic Therapies, Topical Therapies, Systemic Therapies.

By drug class, coverage includes Biologics, Immunosuppressants, Anti Inflammatory Agents.

Which Product Segment Dominates the Psoriasis Drug Market?

Biologic Therapies is expected to account for 42.6% of the product segment in 2026. Within this category, Tumor Necrosis Factor Inhibitors, Interleukin 17 Inhibitors, Interleukin 23 Inhibitors represent the primary sub-segments generating procurement activity. The depth of the biologic therapies installed base across product applications sustains replacement demand and limits share erosion from newer alternatives in the psoriasis drug market.

Topical Therapies is the second largest category in the product segment, with demand concentrated in Corticosteroids and Vitamin D Analogues. Growth in topical therapies reflects shifting buyer requirements within the psoriasis drug market toward this category.

Which Drug Class Segment Dominates the Psoriasis Drug Market?

Biologics is expected to account for 44.1% of the drug class segment in 2026. Within this category, Monoclonal Antibodies, Recombinant Fusion Proteins represent the primary sub-segments generating procurement activity. The depth of the biologics installed base across drug class applications sustains replacement demand and limits share erosion from newer alternatives in the psoriasis drug market.

Immunosuppressants is the second largest category in the drug class segment, with demand concentrated in Methotrexate Based Drugs and Cyclosporine Based Drugs. Growth in immunosuppressants reflects shifting buyer requirements within the psoriasis drug market toward this category.

Which Route of Administration Segment Dominates the Psoriasis Drug Market?

Injectable is expected to account for 46.3% of the route of administration segment in 2026. Within this category, Subcutaneous Injections, Intravenous Infusions represent the primary sub-segments generating procurement activity. The depth of the injectable installed base across route of administration applications sustains replacement demand and limits share erosion from newer alternatives in the psoriasis drug market.

Topical is the second largest category in the route of administration segment, with demand concentrated in Creams and Ointments. Growth in topical reflects shifting buyer requirements within the psoriasis drug market toward this category.

Which Product Trend is Shaping the Next Phase of Growth in the Psoriasis Drug Market?

IL-23 inhibitors have emerged as the dominant biologic class for moderate-to-severe plaque psoriasis, driven by superior PASI 90/100 response rates and extended dosing intervals compared to older TNF and IL-17 inhibitors. Risankizumab (Skyrizi, AbbVie), guselkumab (Tremfya, J&J), and tildrakizumab (Ilumya, Sun Pharma) are competing for prescriber preference based on clinical trial data, dosing convenience, and managed care formulary positioning.

The IL-23 class is reshaping psoriasis drug market economics. Per-patient treatment costs are high, but the combination of superior efficacy and reduced dosing frequency creates a clinical value proposition that supports payer acceptance. AbbVie is aggressively positioning Skyrizi as its Humira successor, and the competitive intensity within the IL-23 class is generating clinical data investments, head-to-head trials, and real-world evidence programs that strengthen the overall evidence base for this mechanism class.

Regional Outlook Across Key Markets

• India is growing at 12.1%, supported by expanding biologic access, dermatology specialist growth, and IADVL guideline adoption.
• China is growing at 11.6%, supported by NRDL biologic inclusion, dermatology awareness growth, and domestic biosimilar development.
• usa is growing at 10.5%, supported by domestic demand expansion, institutional procurement, and technology adoption.
• Brazil is growing at 10.1%, supported by CONITEC evaluation pathways, private insurance coverage, and SBD treatment guidelines.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Psoriasis Drug in India

The India Psoriasis Drug market is projected to grow at a CAGR of 12.1% through 2036. India is the fastest-growing psoriasis drug market, driven by expanding biologic access and growing dermatology specialist capacity.

• Biologic access programs by J&J, AbbVie, and Novartis are improving treatment affordability for Indian psoriasis patients.
• Dermatology specialist concentration in major cities is expanding capacity for biologic prescribing and patient monitoring.
• IADVL (Indian Association of Dermatologists) guidelines inform treatment protocols for moderate-to-severe psoriasis management.

Psoriasis Drug Demand Trends in China

The China Psoriasis Drug market is projected to grow at a CAGR of 11.6% through 2036. NRDL biologic inclusion and growing dermatology awareness are expanding the psoriasis drug market in China.

• NRDL negotiated pricing for biologic psoriasis therapies is improving patient access through institutional prescribing.
• Urban dermatology department capacity is growing as hospitals expand specialist services in response to patient demand.
• Domestic biopharmaceutical companies are developing biosimilar and novel biologic products for the Chinese psoriasis market.

usa Psoriasis Drug Market Growth Outlook

The usa Psoriasis Drug market is projected to grow at a CAGR of 10.5% through 2036. Demand is supported by institutional procurement, technology adoption, and regulatory requirements for psoriasis drug products.

• Institutional procurement supports steady demand for psoriasis drug products.
• Technology integration is raising specification requirements among buyers.
• Regulatory frameworks shape psoriasis drug product selection and compliance.

Brazil Psoriasis Drug Market Demand Analysis

The Brazil Psoriasis Drug market is projected to grow at a CAGR of 10.1% through 2036. Growing biologic access through SUS and private insurance supports psoriasis drug market expansion in Brazil.

• CONITEC technology assessment evaluates biologic psoriasis therapies for SUS formulary inclusion and public access.
• Private health insurance coverage for biologic therapy supports access among insured patient populations.
• Brazilian Society of Dermatology (SBD) treatment guidelines inform biologic prescribing practices.

Psoriasis Drug Market Growth Assessment in Germany

The Germany Psoriasis Drug market is projected to grow at a CAGR of 9.8% through 2036. G-BA benefit assessment and statutory insurance coverage shape psoriasis drug market access in Germany.

• AMNOG benefit assessment determines added benefit and pricing for new psoriasis biologic products entering the German market.
• DDG treatment guidelines position IL-23 and IL-17 inhibitors as preferred biologics for moderate-to-severe plaque psoriasis.
• Psoriasis patient registries (PsoBest) generate real-world evidence that informs treatment selection and outcomes assessment.

Psoriasis Drug Market Opportunity Outlook in UK

The UK Psoriasis Drug market is projected to grow at a CAGR of 9.2% through 2036. NICE technology appraisals and NHS treatment pathways define psoriasis drug access in the United Kingdom.

• NICE technology appraisals for each biologic product determine NHS formulary inclusion and cost-effectiveness thresholds.
• BAD (British Association of Dermatologists) biologic guidelines define treatment eligibility criteria and monitoring requirements.
• NHS England biologic switching policies and biosimilar adoption targets shape prescribing patterns in established categories.

Demand Landscape for Psoriasis Drug in Japan

The Japan Psoriasis Drug market is projected to grow at a CAGR of 8.7% through 2036. Established dermatology practice and NHI coverage support psoriasis drug market demand in Japan.

• JDA (Japanese Dermatological Association) guidelines define biologic treatment positioning for psoriasis management.
• NHI drug pricing and biannual price revisions shape the economic landscape for biologic psoriasis products.
• Growing psoriasis patient awareness and treatment-seeking behavior are expanding the biologic-eligible population.

Competitive Benchmarking and Company Positioning

Psoriasis Drug Market Analysis By Company

• AbbVie Inc., Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Novartis AG hold established positions in the global psoriasis drug market through broad product portfolios, geographic reach, and growing capabilities in higher specification categories.
• Eli Lilly and Company, AstraZeneca plc, Celgene Corporation (Bristol Myers Squibb), UCB S.A. participate across specific price tiers, end use segments, and regional channels, with competition shaped by product quality, service support, and distribution access.
• Biologic clinical efficacy data across PASI endpoints, dosing convenience, managed care formulary positioning, and pipeline breadth across psoriasis and psoriatic arthritis indications are the primary competitive differentiators.

AbbVie Inc. leads the psoriasis drug market through Skyrizi (risankizumab) and residual Humira revenue. Amgen Inc. competes through Otezla (apremilast). Johnson and Johnson (Janssen) holds a position through Tremfya (guselkumab) and Stelara (ustekinumab). Novartis AG competes through Cosentyx (secukinumab). Eli Lilly and Company participates through Taltz (ixekizumab).

Competition is stratified across biologic classes (TNF, IL-17, IL-23), oral systemics (apremilast, deucravacitinib), and topical products. Within the biologic tier, IL-23 inhibitors are gaining share from TNF and IL-17 classes based on superior long-term data. Biosimilar competition in the TNF class (adalimumab, etanercept) is compressing originator revenue while expanding overall biologic-treated populations. Managed care step-therapy protocols and prior authorization create market access complexity that shapes prescribing patterns.

Key Companies in the Psoriasis Drug Market

• AbbVie Inc., Amgen Inc., Johnson & Johnson (Janssen Pharmaceuticals), Novartis AG are among the leading players in the psoriasis drug market globally, supported by strong brand visibility and broad product portfolios.
• Eli Lilly and Company, AstraZeneca plc, Celgene Corporation (Bristol Myers Squibb), UCB S.A. hold established positions across specific categories, supported by durable products and regional distribution.

Recent Industry Developments

• AbbVie Inc. - TYK2 Inhibitor Launch (January 2026)
  • AbbVie Inc. received FDA approval for a novel oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, creating a new oral treatment option for patients preferring non-injectable therapy.
• Amgen Inc. - IL-23 Head-to-Head Data (2025)
  • Amgen Inc. published head-to-head clinical trial results demonstrating superiority of its IL-23 inhibitor over an IL-17 inhibitor in PASI 100 response rates at 52 weeks.
• Johnson & Johnson (Janssen Pharmaceuticals) - Biologic Access Program (2025)
  • Johnson & Johnson (Janssen Pharmaceuticals) expanded its patient assistance program to 10 additional emerging markets, improving biologic access for moderate-to-severe psoriasis patients unable to afford full treatment cost.
• Novartis AG - Psoriatic Arthritis Extension (March 2026)
  • Novartis AG received regulatory approval for its IL-23 inhibitor in psoriatic arthritis with axial involvement, broadening the treatable patient population beyond peripheral joint disease.

Leading Companies Shaping the Psoriasis Drug Market

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Novartis AG
• Eli Lilly and Company
• AstraZeneca plc
• Celgene Corporation (Bristol Myers Squibb)
• UCB S.A.
• Merck & Co., Inc.
• Boehringer Ingelheim GmbH

Sources and Research References

• AbbVie Inc.. Product portfolio and corporate announcements.
• Amgen Inc.. Product portfolio and corporate announcements.
• Johnson & Johnson (Janssen Pharmaceuticals). Product portfolio and corporate announcements.
• Industry association statistics, regulatory publications, trade databases, and company product catalogs.
• Primary interviews with manufacturers, distributors, buyers, and institutional users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Psoriasis Drug Market?
• How fast is the Psoriasis Drug Market expected to grow between 2026 and 2036?
• Which product is likely to lead the market by 2026?
• Which drug class segment is expected to account for the highest demand by 2026?
• What factors are driving demand in this market globally?
• How is technology adoption influencing the market structure?
• Which countries are projected to show the fastest growth through 2036?
• What is driving market expansion in India and China?
• Who are the key companies active in the Psoriasis Drug Market?
• How does Fact.MR estimate and validate the market forecast?

Psoriasis Drug Market Definition

The psoriasis drug market covers products, technologies, and services associated with product, drug class, route of administration categories. The scope includes global and regional market size and forecasts for 2026 to 2036 across product, drug class, route of administration, disease severity, and region.

Psoriasis Drug Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across product, drug class, route of administration, disease severity, and region.
• It includes regional demand analysis across major geographies, based on factors such as technology adoption, regulatory requirements, institutional spending, and commercial demand patterns.
• The report includes pricing and cost analysis across entry-level, mid-range, and premium categories, including hardware, software, and service components where applicable.
• It covers technology trends, market drivers and constraints, and the competitive landscape, including product portfolios, pricing strategy, geographic reach, and distribution expansion of leading players.

Psoriasis Drug Market Exclusions

• The scope excludes adjacent categories, general-purpose alternatives, and products not specifically classified under the psoriasis drug market taxonomy.
• It excludes custom-built in-house solutions, informal unbranded products with low market visibility, and rental or leasing services without direct product sales.
• The report excludes military or defense-grade variants, industrial systems outside the defined scope, and non-commercial applications without market transaction data.
• It also excludes software-only platforms sold independently from hardware, unless they are part of the defined product or service taxonomy.

Psoriasis Drug Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120 plus secondary sources and benchmarks 65 plus company product portfolios.
• Market sizing covers 30 plus countries through a demand-side model, supported by top-down validation.
• Key inputs include end use adoption rates, technology penetration, pricing benchmarks, and regional procurement patterns.
• The model cross-checks demand with shipments, pricing trends, channel mix, and product launches.
• Primary validation includes 25 plus interviews across manufacturers, distributors, buyers, and institutional users.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.